TITLE

Effect of Folic Acid Supplementation on Indices of Glycemic Control, Insulin Resistance and Lipid Profile in Patients With Type 2 Diabetes Mellitus

AUTHOR(S)
Aghamohammadi khiavi, V.; Pourghassem Gargari, B.; Aliasgharzadeh, A.
PUB. DATE
November 2011
SOURCE
Iranian Journal of Endocrinology & Metabolism;Nov2011, Vol. 13 Issue 4, p424
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: This study was performed to determine the effects of supplementation of folate on indices of glycemic control, insulin resistance and lipid profile in in men with type 2 diabetes, under metformin (at least 1500mg daily) treatment. Materials and Methods: This was a double-blind randomized controlled clinical trial, in which 68 men with type 2 diabetes participated with written consents. Patients were randomly divided in two groups; folic acid 5mg/day and placebo. All the patients received the tablets for 8 weeks. Anthropometric and nutrient intakes data were obtained from each patient, and baseline and 8th week fasting blood glucose, HbA1C, serum insulin, insulin resistance, serum total cholestrol, TG, LDL-C, HDL-C, serum folate and plasma homocysteine were measured. Results: Supplementation with folic acid led to 6.3 percent decrease in HbA1C (P=0.019), 9.5 percent decrease in fasting blood glucose (P=0.006), 15.1 percent decrease in serum insulin (P=0.028), 17.2 percent decrease in insulin resistance (P=0.043) and 20 percent decrease in plasma homocysteine (P<0.001), 18.4 percent increase in serum folate (P<0.001). No significant changes occurred in the placebo group (P>0.05). Conclusion: A pharmacological dose of folic acid supplementation decreased plasma level of homocysteine and improved glycemic control, insulin resistance and folate levels, a finding which sugqests a safe and inexpensive therapy for lowering homocysteine and improving the overall management of diabetic patients.
ACCESSION #
73351335

 

Related Articles

  • Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial. An Pan; Jianqin Sun; Yanqiu Chen; Xingwang Ye; Huaixing Li; Zhijie Yu; Yanfang Wang; Wenjia Gu; Xinyi Zhang; Xiafei Chen; Demark-Wahnefried, Wendy; Yong Liu; Xu Lin // PLoS Clinical Trials;Nov2007, Vol. 4 Issue 11, p1 

    Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin...

  • Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. Tanaka, Kumiko; Saisho, Yoshifumi; Manesso, Erica; Tanaka, Masami; Meguro, Shu; Irie, Junichiro; Sugiura, Hiroaki; Kawai, Toshihide; Jinzaki, Masahiro; Cobelli, Claudio; Itoh, Hiroshi // Clinical Drug Investigation;Oct2015, Vol. 35 Issue 10, p675 

    Background and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming one of the major therapeutic options for the treatment of type 2 diabetes mellitus (T2DM). This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta...

  • Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. Gu, Shuyan; Shi, Jihao; Tang, Zhiliu; Sawhney, Monika; Hu, Huimei; Shi, Lizheng; Fonseca, Vivian; Dong, Hengjin // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Metformin is the first-line oral hypoglycemic agent for type 2 diabetes mellitus recommended by international guidelines. However, little information exists comparing it with acarbose which is also commonly used in China. This study expanded knowledge by combining direct and...

  • Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial. Brouwer, Annelies; van Raalte, Daniël H.; Diamant, Michaela; Rutters, Femke; van Someren, Eus J. W.; Snoek, Frank J.; Beekman, Aartjan T. F.; Bremmer, Marijke A. // BMC Psychiatry;2015, Vol. 15 Issue 1, p1 

    Background: Major depression and type 2 diabetes often co-occur. Novel treatment strategies for depression in type 2 diabetes patients are warranted, as depression in type 2 diabetes patients is associated with poor prognosis and treatment results. Major depression and concurrent sleep disorders...

  • Fighting Obesity and High Blood Sugar. GOEPP, JULIUS // Life Extension;Nov2010, Vol. 16 Issue 11, p46 

    The article reports on the health benefits that have been associated with the anti-diabetes drug metformin, including the reduction of blood sugar and weight gain, the prevention of several types of cancer and a slowing of the human aging process. A discussion of research which has investigated...

  • thiazolidinediones. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p740 

    An encyclopedia entry for "thiazolidinediones" is presented. It pertains to a group of oral hypoglycaemics that are utilized in the treatment of type 2 diabetes mellitus. Thiazolidinedione is sometimes pertained as glitazones. It functions by cutting the body cells' resistance to insulin and are...

  • Metabolic disease: Mitochondrial uncoupler reverses diabetes. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Dec2014, Vol. 13 Issue 12, p885 

    The article discusses the development of insulin resistance and hyperglycaemia which use to treat type 2 diabetes (T2D) by reducing the accumulation of lipids in metabolically sensitive organs. It examines the impact of mitochondrial uncoupler to energy inefficiency and increased energy...

  • Maximize benefits of metform in DM2. Kuritzky, Louis // Primary Care Reports;May2010 Supplement, p9 

    The article discusses research being done on the efficacy of metformin monotherapy in controlling glucose in type 2 diabetes, which references a study by J. B. Brown and colleagues published in a 2010 issue of the journal "Diabetes Care."

  • For type 2 diabetes, after metformin, what next? Kuritzky, Louis // Primary Care Reports;Jul2010 Clinical Briefs, p14 

    The article discusses the therapeutic choices for type-2 diabetes following initial treatment with metformin.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics